Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
Location: United States, California, San Carlos
Employees: 11-50
Total raised: $113M
Founded date: 2014
Investors 5
| Date | Name | Website |
| - | Mission Bi... | missionbio... |
| - | MBC BioLab... | mbcbiolabs... |
| - | For Good V... | forgoodven... |
| 28.06.2021 | Abingworth... | abingworth... |
| - | Chiesi Ven... | chiesivent... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 25.06.2021 | Series B | $68M | - |
| 07.08.2019 | Series B | $33M | - |
| 26.11.2016 | Series A | $12M | Chiesi Ven... |
Mentions in press and media 11
| Date | Title | Description | Source |
| 25.06.2021 | Glycomine Raises $68M in Series B Funding | Glycomine, Inc., a San Carlos, Calif.-based biotechnology company focused on developing new therapie... | finsmes.co... |
| 23.06.2021 | Glycomine Closes $68 Million Series B to Advance into Clinic... | Glycomine, Inc., a biotechnology company focused on developing new therapies for orphan diseases, to... | marketscre... |
| 23.06.2021 | Glycomine Closes $68M Series B Funding | SAN CARLOS, CA, Glycomine has closed a $68 million Series B financing led by Abingworth and Sanofi... | vcnewsdail... |
| 23.06.2021 | Glycomine Closes $68 Million Series B to Advance into Clinic... | - | abingworth... |
| 07.08.2019 | Glycomine Closes $33 Million Series B | Glycomine, Inc., a biotechnology company focused on developing new therapies for rare diseases, toda... | citybizlis... |
| 07.08.2019 | Glycomine Raises $33M in Series B Financing | Glycomine, Inc., a San Carlos, CA-based biotechnology company focused on developing new therapies fo... | finsmes.co... |
| 26.11.2016 | Chiesi Ventures Joins $12M Series A for Glycomine | Glycomine, Inc. a biotechnology company developing a new generation of replacement therapies for rar... | citybizlis... |
| 17.11.2016 | Term Sheet — Thursday, November 17 | WHERE ARE THEY NOW? In today’s issue of Term Sheet, I’m providing updates on some of the stories we’... | fortune.co... |
| 16.11.2016 | Rare disease biotech Glycomine raises $12M, with help from C... | In its Series A announced today Glycomine, an early-stage biotech working on replacement therapies f... | fiercebiot... |
| 16.11.2016 | Glycomine Inks $12M Series A Financing | SAN FRANCISCO, CA, Biotechnology company developing a new generation of replacement therapies for ... | vcnewsdail... |
Show more